Home » Stocks » Galectin Therapeutics

Galectin Therapeutics Inc. (GALT)

Stock Price: $2.65 USD -0.08 (-2.93%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 151.13M
Revenue (ttm) n/a
Net Income (ttm) -14.48M
Shares Out 57.03M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $2.65
Previous Close $2.73
Change ($) -0.08
Change (%) -2.93%
Day's Open 2.70
Day's Range 2.59 - 2.74
Day's Volume 278,088
52-Week Range 1.50 - 4.50

More Stats

Market Cap 151.13M
Enterprise Value 107.80M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 57.03M
Float 41.09M
EPS (basic) -0.29
EPS (diluted) -0.27
FCF / Share -0.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.55M
Short Ratio 29.38
Short % of Float 18.22%
Beta 2.41
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.79
Revenue n/a
Operating Income -14.66M
Net Income -14.48M
Free Cash Flow -11.94M
Net Cash 43.33M
Net Cash / Share 0.76
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -35.27%
ROE -58.37%
ROIC 1,640.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $2.65
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-13.44-13.60-16.25-21.48-20.08-15.43-12.10-9.90-10.41-4.88
Net Income-13.29-13.90-16.24-21.44-20.03-15.79-20.85-9.68-10.92-5.63
Shares Outstanding52.2439.4135.5229.2224.1221.8516.8715.1311.999.38
Earnings Per Share-0.39-0.38-0.49-0.76-0.88-0.78-1.30-0.72-1.06-0.93
Operating Cash Flow-10.85-10.18-15.89-16.41-16.98-12.43-7.48-7.50-5.68-3.10
Capital Expenditures--------0.01-0.01-
Free Cash Flow-10.85-10.18-15.89-16.41-16.98-12.43-7.48-7.51-5.68-3.10
Cash & Equivalents47.488.253.0515.3625.8529.1310.499.366.405.95
Net Cash / Debt47.488.253.0515.3625.8529.1310.499.366.405.95
Book Value43.875.18-0.5310.2918.0421.201.481.17-2.13-1.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Galectin Therapeutics Inc.
Country United States
Employees 4
CEO Harold H. Shlevin

Stock Information

Ticker Symbol GALT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GALT


Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.